Soleno Therapeutics (SLNO) Stock
Rare disease company developing treatments for hormonal conditions. Here's the price, business snapshot, and what's worth knowing about Soleno Therapeutics in November 2026.
Soleno Therapeutics (ticker: SLNO) is a clinical-stage biotechnology company focused on developing treatments for rare endocrine and metabolic disorders. Investors should know it concentrates on a small number of specialised product candidates intended to address conditions with limited existing therapies. As a clinical-stage firm, valuation is closely tied to trial results, regulatory milestones and potential partnerships or licensing deals. The stock’s market capitalisation is approximately $3.57bn, reflecting investor expectations about future clinical and commercial progress. Typical investor considerations include high clinical and regulatory risk, potential for significant share-price volatility around news flow, and a longer time horizon for commercial returns if candidates are approved. This summary provides general educational information and is not personalised investment advice; prospective investors should carry out further research and consider their risk tolerance before making decisions.
Soleno Therapeutics (SLNO) Stock Forecast
Analyst price target, next 12 months
$113.54
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Soleno Therapeutics stock, expecting its price to rise significantly.
Financial Health
Soleno Therapeutics is generating strong revenue and cash flow, indicating solid business performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage pipeline
Investors watch trial progress and regulatory milestones as primary value drivers, though outcomes are uncertain and can cause volatility.
Potential catalysts
Upcoming readouts, approvals or partnerships could materially affect valuation, but clinical and regulatory risks remain significant.
Niche market focus
Targeting rare endocrine disorders can mean high unmet need and pricing power if approved, balanced by small patient populations and commercial uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
